Clinical Trial Update: A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer Patients [Phase 3]

View source ↗

Summary

A Phase III randomized trial evaluating Taxotere with Aptosyn versus Taxotere with placebo in non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Aptosyn
• Taxotere (docetaxel)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: COMPLETED